Analysts Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $50.83

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned an average rating of “Hold” from the six analysts that are currently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $50.83.

Several equities analysts have recently commented on the company. Barclays upped their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Wells Fargo & Company upped their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. JPMorgan Chase & Co. upped their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Benchmark reaffirmed a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a report on Saturday, October 19th.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently added to or reduced their stakes in OMCL. Nisa Investment Advisors LLC lifted its position in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares during the period. GAMMA Investing LLC lifted its position in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the period. EntryPoint Capital LLC lifted its position in Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares during the period. CWM LLC lifted its position in Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares during the period. Finally, 1620 Investment Advisors Inc. lifted its position in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Trading Down 2.2 %

NASDAQ:OMCL opened at $47.81 on Friday. The firm has a market capitalization of $2.21 billion, a PE ratio of -124.56, a price-to-earnings-growth ratio of 47.07 and a beta of 0.81. The stock has a 50 day moving average of $44.07 and a 200-day moving average of $36.55. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.